Tag: 300-400

Stereoselective pharmacokinetics of (R)-(+)- and (S)-(-)-rabeprazole in human using chiral LC-MS/MS after administration of rabeprazole sodium enteric-coated tablet was written by Sun, Lu-Ning;Shen, Yi-Wen;Ying, Yu-Wen;Li, Duo;Li, Teng-Fei;Zhang, Xue-Hui;Zhao, Ping;Ding, Li;Wang, Yong-Qing. And the article was included in Chirality in 2018.Recommanded Product: 117976-90-6 The following contents are mentioned in the article:

Rabeprazole is an effective proton pump inhibitor to treat acid-related diseases. To achieve the simultaneous determination of rabeprazole enantiomers in human plasma, a chiral LC-MS/MS method was developed and validated. Acetonitrile including 0.1% ammonium were used as protein precipitating agent. Analytes were separated within 8 min on a Chiralpak IC column (4.6 mm 脳 150 mm, 5 渭m). The mobile phase was 10 mM ammonium acetate including 0.2% acetic acid-acetonitrile (35:65, volume/volume). An API 4000 mass spectrometer was used as detector for the anal., and the multiple reactions monitoring transitions of m/z 360.1 鈫?242.2 and 346.1 鈫?198.1 were opted for quantifying rabeprazole enantiomers and internal standard Matrix effects were not apparent for each enantiomer and internal standard (esomeprazole), the calibration curves were linear over the concentration of 0.500 to 400 ng路mL^-1, the intra-run precisions were below 5.4%, the inter-run precisions were below 9.9%, and the accuracy was between -9.2% and 9.3%. There was no chiral inversion observed during sample storage, preparation procedure, and anal., demonstrating that analytes were stable in this study. This method was applied to the stereoselective pharmacokinetic study of (R)-(+)- and (S)-(-)-rabeprazole after oral administration of 10-mg rabeprazole sodium enteric-coated tablet in healthy Chinese subjects. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6Recommanded Product: 117976-90-6).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. The pharmacophore of imidazole exists in bioactive compounds including amino acids, plant growth regulators and therapeutic agents.n increase of the alkyl chain length of the alcohols. Recommanded Product: 117976-90-6

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Viral Evolution and Immunology of SARS-CoV-2 in a Persistent Infection after Treatment with Rituximab was written by Van der Moeren, Nathalie;Selhorst, Philippe;Ha, My;Heireman, Laura;Van Gaal, Pieter-Jan;Breems, Dimitri;Meysman, Pieter;Laukens, Kris;Verstrepen, Walter;Van Gasse, Natasja;Ogunjimi, Benson;Arien, Kevin K.;Naesens, Reinout. And the article was included in Viruses in 2022.Formula: C16H21Cl2N3O2 The following contents are mentioned in the article:

Prolonged shedding of SARS-CoV-2 in immunocompromised patients has been described. Furthermore, an accumulation of mutations of the SARS-CoV-2 genome in these patients has been observed We describe the viral evolution, immunol. response and clin. course of a patient with a lymphoma in complete remission who had received therapy with rituximab and remained SARS-CoV-2 RT-qPCR pos. for 161 days. The patient remained hospitalised for 10 days, after which he fully recovered and remained asymptomatic. A progressive increase in Ct-value, coinciding with a progressive rise in lymphocyte count, was seen from day 137 onward. Culture of a nasopharyngeal swab on day 67 showed growth of SARS-CoV-2. Whole genome sequencing (WGS) demonstrated that the virus belonged to the wildtype SARS-CoV-2 clade 20B/GR, but rapidly accumulated a high number of mutations as well as deletions in the N-terminal domain of its spike protein. SARS-CoV-2 persistence in immunocompromised individuals has important clin. implications, but halting immunosuppressive therapy might result in a favorable clin. course. The long-term shedding of viable virus necessitates customized infection prevention measures in these individuals. The observed accelerated accumulation of mutations of the SARS-CoV-2 genome in these patients might facilitate the origin of new VOCs that might subsequently spread in the general community. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Formula: C16H21Cl2N3O2).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. 1H-imidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is a tautomer of a 4H-imidazole. The pharmacophore of imidazole exists in bioactive compounds including amino acids, plant growth regulators and therapeutic agents.n increase of the alkyl chain length of the alcohols. Formula: C16H21Cl2N3O2

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations was written by Cramer, Paula;Tausch, Eugen;von Tresckow, Julia;Giza, Adam;Robrecht, Sandra;Schneider, Christof;Fuerstenau, Moritz;Langerbeins, Petra;Al-Sawaf, Othman;Pelzer, Benedikt W.;Fink, Anna Maria;Fischer, Kirsten;Wendtner, Clemens-Martin;Eichhorst, Barbara;Kneba, Michael;Stilgenbauer, Stephan;Hallek, Michael. And the article was included in Blood in 2021.Safety of 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid The following contents are mentioned in the article:

Fifty-one of 189 evaluable patients from 3 prospective phase 2 trials evaluating a sequential targeted treatment had high-risk chronic lymphocytic leukemia (CLL) with a 17p deletion, TP53 mutation, or both. Twenty-seven patients started treatment with bendamustine debulking before induction and maintenance treatment, which was ibrutinib/ofatumumab (IO) in 21 patients, ibrutinib/obinutuzumab (IG) in 13, and venetoclax/obinutuzumab (AG) in 17. The primary end point was overall response rate after 8 mo of induction treatment, which was 81%, 100%, and 94% for IO, IG, and AG, resp. Minimal residual disease (MRD) was undetectable (uMRD) in peripheral blood (<10^-4 by flow cytometry) in 0%, 23%, and 82% of patients, resp. Median progression-free survival (PFS) was 45 mo. Seventeen patients discontinued maintenance treatment due to uMRD: 9 progressed, 2 died without progression (median PFS, 28 mo after discontinuation of treatment), and 6 remained in remission after a median observation time of 46 mo (range, 6-47 mo) after treatment discontinuation. Thus, MRD-guided fixed-duration therapies combining obinutuzumab with venetoclax or ibrutinib can induce deep and durable remissions in CLL patients with high-risk genetic lesions, which can persist after treatment discontinuation (due to a predefined fixed-duration or MRD-guided early termination). The median PFS was 45 mo. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Safety of 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. Imidazole has been usedin the lysis, wash and elution buffer for the purification of histidine tagged Sonic Hedgehog(shh-N) protein, in elution buffer in stepwise gradient for the purification of histidine tagged aldo keto reductases using nickel affinity chromatography, as a component of homogenization buffer for the purification of phagosomal compartments from dendritic cells.Safety of 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Fabrication of pH-Responsive Hydrogel and Its In Vitro and In Vivo Evaluation was written by Tulain, Ume Ruqia;Ahmad, Mahmood;Rashid, Ayesha;Malik, Muhammad Zubair;Iqbal, Furqan Muhammad. And the article was included in Advances in Polymer Technology in 2018.Related Products of 117976-90-6 The following contents are mentioned in the article:

The present research work deals with the development of pH-responsive hydrogel by free radical polymerization in aqueous media to protect the rabeprazole sodium from acidic environment of stomach. Swelling behavior of hydrogels that was observed in buffer of various pH indicated highly pH-dependent swelling of hydrogels. Characterization of pH-responsive hydrogels by FTIR, SEM, and thermal anal. revealed that hydrogel has porous structure, favors swelling, drug loading, and drug release at a specific site in gastrointestinal tract and thermally more stable than parent polymer. In comparison with simple drug solution and hydrogel formulations, pharmacokinetic parameters of hydrogels formulations showed a significant difference in C_max values of (CMC-g-AA) CA and the same oral dose of rabeprazole sodium was 87.28 卤 12.671 and 61.263 卤 5.37 ng/mL, resp., T_max of graft copolymer matrixes CA (4.43 h) was significantly (P < 0.05) higher than drug solution (1 h) and area under curves (AUCs) for CA (952.25 卤 191 ng路/mL) was significantly (P < 0.05) higher than the drug solution (83.67 卤 8.28 ng路/mL) indicated the effect of dosage form would last for longer duration. Thus, in vitro and in vivo drug release studies of hydrogels proved their controlled release behavior with preferential delivery into alk. pH environment and for a prolonged period of time. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6Related Products of 117976-90-6).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. The solubility of imidazoles in ethers is lower than that in alcohols and decreases with increasing chain length of the ethers . In contrast, the solubility of benzimidazoles in alcohols (C3鈥揅6) is higher than in water and generally decreases with a Imidazole derivatives have antibacterial, antifungal and anticancer functionality. It interacts with DNA and also binds to protein and stops cell division.Related Products of 117976-90-6

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Enantioseparation and modelling study of six proton pump inhibitors on a novel 3, 5-dichloro-phenylcarbamated 尾-cyclodextrin chemically bonded chiral stationary phase by high performance liquid chromatography was written by Li, Meng;Jiang, Zhen;Guo, Xingjie;Di, Xin;Yu, Jia. And the article was included in Microchemical Journal in 2021.Application In Synthesis of Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide The following contents are mentioned in the article:

A fully substituted 尾-cyclodextrin derivative chem. bonded chiral stationary phase for high performance liquid chromatog., named MDCPC was prepared by linking 3, 5-dichloro-phenylcarbamated mono-6-ethylenediamine-尾-cyclodextrin to the surface of silica support. The as-prepared MDCPC was successfully characterized by SEM, fourier transform IR spectra, solid state NMR spectra, elemental anal. and thermogravimetric anal. The enantioselectivity of MDCPC was systematically evaluated by using proton pump inhibitors including omeprazole, lansoprazole, pantoprazole sodium, ilaprazole, rabeprazole sodium and tenatoprazole under the normal phase, polar organic phase, and reversed phase conditions. Effects of the mobile phase compositions and buffers on enantioseparation were investigated in different modes. As a result, MDCPC showed a better chromatog. performance in enantioselectivity, and all tested compounds were successfully enantiosepd. Findings of the mol. docking showed that hydrogen bonding, hydrophobic interaction and inclusion complexation played an important role in improving enantioselectivity. Addnl., good repeatability, column-to-column reproducibility and stability of MDCPC were observed by the study of chiral or achiral separation As a novel chiral stationary phase, MDCPC was supposed to be a promising prospect in the further anal. of chiral drugs. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6Application In Synthesis of Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. Imidazole has become an important synthon in the development of new drugs. Many drugs contain an imidazole ring, such as certain antifungal drugs, the nitroimidazole series of antibiotics, and the sedative midazolam.Application In Synthesis of Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Identification of Novel Mutant (R132H) Isocitrate Dehydrogenase 1 Inhibitors for Glioma Therapy was written by Murali, Poornimaa;Karuppasamy, Ramanathan. And the article was included in Journal of Computational Biophysics and Chemistry in 2022.Name: 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid The following contents are mentioned in the article:

Neomorphic transformations in isocitrate dehydrogenase 1 (IDH1) are the key mutations prevalently found in various cancers including glioma. Recently identified mIDH1 specific inhibitors showed modest brain penetrating potential and dose-limiting toxicity. Herein, we elucidate virtual screening strategies to discover persuasive mIDH1 inhibitors from the approved subset of the DrugBank database consisting of 2715 mols. Initially, a structural similarity search identified a total of 1432 lead mols. The resultant compounds were inspected by mol. docking along with MM-GBSA and ADMET analyses. Altogether, the analyses identified Abemaciclib as the hit against mIDH1. Notably, abemaciclib was able to form hydrogen bond interaction with active site residues of mIDH1 protein. In the end, the dynamic behavior of the hit complex was also examined using mol. dynamics simulation studies. The outcome of the study culminates that the hit complex was stable throughout the simulation period of 100ns. It is worth noting that benzimidazole moiety of abemaciclib was reported to show inhibitory activity against glioma cells. Overall, these findings highlight that abemaciclib has the potential as a lead mol. against glioma. Indeed, the screened hit compound could be further explored for the development of mIDH1 inhibitor with great brain penetrating ability and low toxicity. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Name: 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. Imidazole has been usedin the lysis, wash and elution buffer for the purification of histidine tagged Sonic Hedgehog(shh-N) protein, in elution buffer in stepwise gradient for the purification of histidine tagged aldo keto reductases using nickel affinity chromatography, as a component of homogenization buffer for the purification of phagosomal compartments from dendritic cells.Name: 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

A phase 3, randomized study of ofatumumab combined with bendamustine in rituximab-refractory iNHL (COMPLEMENT A + B study) was written by Rummel, Mathias J.;Janssens, Ann;MacDonald, David;Keating, Mary-Margaret;Zaucha, Jan M.;Davis, Jaclyn;Lasher, Janet;Babanrao Pisal, Chaitali;Izquierdo, Miguel;Friedberg, Jonathan W.. And the article was included in British Journal of Haematology in 2021.Related Products of 16506-27-7 The following contents are mentioned in the article:

Summary : The standard of care for indolent non-Hodgkin lymphoma (iNHL) is rituximab, an anti-CD20 antibody, with/without chemotherapy. However, multiple relapses are common in these patients. This phase 3, randomized study compared outcomes of a combination of ofatumumab (a second-generation anti-CD20 antibody) and bendamustine, with bendamustine alone in patients unresponsive to prior rituximab-based treatment. Overall, 346 patients were randomized to receive either the combination or bendamustine alone. Bendamustine was given for 鈮? cycles and ofatumumab for 鈮?2 cycles. The primary end-point was progression-free survival (PFS) after 215 protocol-defined events assessed by independent review committee (IRC). Median IRC-assessed PFS was 16路7 and 13路8 mo in the combination and monotherapy arms resp. [hazard ratio (HR) = 0路82; P = 0路1390]. Median overall survival (OS) was 58路2 and 51路8 mo in the combination and monotherapy arms resp. (HR = 0路89, P = 0路4968). The safety profile was consistent with previous reports. Overall, 73% and 80% of patients in the combination and monotherapy arms, resp., experienced a 鈮rade 3 adverse event. The study did not meet its primary end-point. No significant improvement in PFS and OS was seen with the combination of ofatumumab and bendamustine as compared with bendamustine alone in rituximab-refractory iNHL (NCT01077518). This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Related Products of 16506-27-7).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. Imidazole derivatives have antibacterial, antifungal and anticancer functionality. It interacts with DNA and also binds to protein and stops cell division.Related Products of 16506-27-7

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Low absolute lymphocyte count is a poor prognostic factor for untreated advanced follicular lymphoma treated with rituximab plus bendamustine: results of the prospective phase 2 CONVERT trial was written by Rai, Shinya;Inoue, Hiroaki;Hanamoto, Hitoshi;Matsuda, Mitsuhiro;Maeda, Yasuhiro;Wada, Yusuke;Haeno, Takahiro;Watatani, Yosaku;Kumode, Takahiro;Hirase, Chikara;Espinoza, J. Luis;Morita, Yasuyoshi;Tanaka, Hirokazu;Tatsumi, Yoichi;Matsumura, Itaru. And the article was included in International Journal of Hematology in 2021.Reference of 16506-27-7 The following contents are mentioned in the article:

The aim of this trial is to evaluate the utility of rituximab-bendamustine (R-B) for untreated advanced follicular lymphoma (FL) showing non-optimal response (nOR) to R-CHOP, and to identify clin. prognostic factors for FL patients receiving R-B. Patients who failed to achieve complete response/complete response unconfirmed (CR/CRu) [nOR-group] after 2 cycles of R-CHOP subsequently received 6 cycles of R-B. The primary endpoint was the 3-yr progression-free survival (PFS) rate. Secondary endpoints included determination of prognostic factors. Fifty-six patients initially received R-CHOP, 43/56 patients (76.8%) were judged as nOR, and 33/43 patients (76.7%) completed 6 cycles of R-B. At a median follow-up of 50.6 mo in the nOR-group, the 3-yr PFS rate was 69.0%, and the 3-yr overall survival (OS) rate was 92.7%. The most common toxicities associated with R-B were grade 3-4 lymphopenia (93.0%) and neutropenia (74.4%), both of which were manageable. A multivariate anal. including dose intensity, serum soluble interleukin-2 receptor, and FL international prognostic index-2 revealed low absolute lymphocyte count (< 869/螠L) at diagnosis was an independent poor prognostic factor for both PFS and OS in the R-B-treated nOR-group. This result was further confirmed in validation cohorts including R-B-treated de novo (n = 40) and relapsed (n = 49) FL patients. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Reference of 16506-27-7).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. The pharmacophore of imidazole exists in bioactive compounds including amino acids, plant growth regulators and therapeutic agents.n increase of the alkyl chain length of the alcohols. Reference of 16506-27-7

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Bendamustine-EAM versus R-BEAM after high-dose cytarabine-based induction in newly diagnosed patients with mantle cell lymphoma, a LYSA retrospective study was written by Costes-Tertrais, Domitille;Hueso, Thomas;Gastinne, Thomas;Thieblemont, Catherine;Oberic, Lucie;Bouabdallah, Krimo;Garciaz, Sylvain;Tchernonog, Emmanuelle;Dartigeas, Caroline;Ribrag, Vincent;Fogarty, Patrick;Casasnovas, Rene-Olivier;Houot, Roch;Delette, Caroline;Malak, Sandra;Fornecker, Luc-Matthieu;Gressin, Remy;Damaj, Gandhi;Le Gouill, Steven. And the article was included in Bone Marrow Transplantation in 2022.Electric Literature of C16H21Cl2N3O2 The following contents are mentioned in the article:

Cytarabine-based immuno-chemotherapy followed by autologous stem cell transplantation (ASCT) consolidation is standard of care for fit patients with Mantle Cell Lymphoma (MCL). BEAM (Carmustine, Etoposide, Aracytine, Melphalan) is among the most frequently used conditioning regimen. Studies comparing BEAM with Bendamustine-EAM (BeEAM) have suggested that patients treated with BeEAM have a better progression-free survival (PFS). We performed a cross-study anal. to better evaluate BeEAM. Thirty-five patients from a retrospective study who received R-DHAP/BeEAM were compared to 245 patients from the LyMa trial (NCT00921414) who all received R-DHAP followed by R-BEAM. PFS and Overall Survival (OS) were estimated using Kaplan-Meier methods. At 2 years there was no difference between R-BEAM and BeEAM in either PFS (84.9% vs. 87.9%; p = 0.95) or OS (91.8% vs. 94.2%; p = 0.30). Analyses were repeated on a propensity score to reduce biases. Each patient from the BeEAM cohort (n = 30) was matched to three patients from the R-BEAM cohort (n = 90) for age, sex, MIPI score, pre-transplant status disease and rituximab maintenance (RM). PFS and OS at 2 years remained similar between R-BEAM and BeEAM with more renal toxicity in BeEAM group. MCL patients who received R-DHAP induction before ASCT have similar outcome after R-BEAM or BeEAM conditioning regimen. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Electric Literature of C16H21Cl2N3O2).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. 1H-imidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is a tautomer of a 4H-imidazole. This ring system is present in important biological building blocks, such as histidine and the related hormone histamine.Electric Literature of C16H21Cl2N3O2

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Bendamustine in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: A phase II trial was written by Kumar, Sudhir;Sharma, Atul;Malik, Prabhat Singh;Gogia, Ajay;Pathak, Neha;Sahoo, Ranjit Kumar;Gupta, Ritu;Prasad, Chandra Prakash;Kumar, Lalit. And the article was included in British Journal of Haematology in 2022.Safety of 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid The following contents are mentioned in the article:

Treatment of patients with resistant/refractory multiple myeloma (MM) is an unmet need. In this phase II study, author evaluated the role of bendamustine, pomalidomide and dexamethasone combination in this setting. Between Feb. 2020 and Dec. 2021, 28 patients were recruited. Patients received bendamustine 120 mg/m²day 1, pomalidomide 3 mg days 1-21, and dexamethasone 40 mg days 1, 8, 11, 22, regimen given for a maximum of six cycles. The median (range) age of the patients was 54 (30-76) years and 15 (53.6%) were males. Patients had received a median (range) of three (two-six) prior lines and 85.7% were refractory to both lenalidomide and bortezomib. The primary end-point was the overall response rate (ORR) defined as 鈮artial response after at least three cycles. Secondary objectives were toxicity, progression-free survival (PFS), time to progression and overall survival (OS). An intent-to-treat anal. was done. An ORR of 57.6% was achieved. Patients with extramedullary myeloma had a better response rate. At a median follow-up of 8.6 mo, the median PFS and OS were 6.2 and 9.7 mo resp. Toxicity was manageable; mainly haematol. (neutropenia, 46.4%; anemia, 42.8%; and thrombocytopenia, 7.1%). Bendamustine, pomalidomide and dexamethasone could be a novel combination for the heavily pretreated, lenalidomide-refractory myeloma population. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Safety of 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. Imidazole is incorporated into many important biological compounds. The most pervasive is the amino acid histidine, which has an imidazole side-chain. Histidine is present in many proteins and enzymes, e.g. by binding metal cofactors, as seen in hemoglobin.Safety of 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem